Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
Persistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the cha...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Index Copernicus International S.A.
2015-04-01
|
Series: | Postępy Higieny i Medycyny Doświadczalnej |
Subjects: | |
Online Access: | http://phmd.pl/gicid/01.3001.0009.6529 |
id |
doaj-13a7fa7160bc4721ab061025a76fe4a6 |
---|---|
record_format |
Article |
spelling |
doaj-13a7fa7160bc4721ab061025a76fe4a62020-11-24T23:15:40ZengIndex Copernicus International S.A.Postępy Higieny i Medycyny Doświadczalnej0032-54491732-26932015-04-016954354810.5604/01.3001.0009.652901.3001.0009.6529Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccineIwona Hus0Joanna Gonet-Sebastianka1Agata Surdacka2Agnieszka Bojarska-Junak3Jacek Roliński4Department of Clinical Transplantology, Medical University of Lublin, PolandDepartment of Gynaecology and Obstetrics, Specialist Hospital in Jasło, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, PolandDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, PolandPersistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the changes in the immune system that occur within four weeks of the first dose of HPV-16/18 ASO4-adjuvanted vaccine. Assessment of the percentages of selected cell populations in peripheral blood of 20 healthy volunteers vaccinated with Cervarix was performed using flow cytometry. The analysis revealed an increase in the proportion of activated B and CD4+ T helper cells and an absence of significant differences in cytotoxic CD8+ T lymphocytes, indicating activation of the humoral response after vaccination, without a significant effect on cellular response. There were no significant changes in the NK cell population, and there was a reduction of the percentage of NKT-like cells, which may result from expiry of the primary response at the time of analysis. The presented results are preliminary, and in the context of the increasing use of the anti-HPV vaccine, it would be worth continuing the study in larger groups of patients and at earlier and later time points in combination with the measurement of specific anti-HPV16 and -HPV18 antibody levels. Such an assessment could therefore contribute not only to better understanding of the exact mechanism of action of the vaccine, but also to defining the immunological parameters that determine its effectiveness. http://phmd.pl/gicid/01.3001.0009.6529cervical cancerhuman papilloma virus (HPV)prophylactic vaccineimmune cell response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Iwona Hus Joanna Gonet-Sebastianka Agata Surdacka Agnieszka Bojarska-Junak Jacek Roliński |
spellingShingle |
Iwona Hus Joanna Gonet-Sebastianka Agata Surdacka Agnieszka Bojarska-Junak Jacek Roliński Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine Postępy Higieny i Medycyny Doświadczalnej cervical cancer human papilloma virus (HPV) prophylactic vaccine immune cell response |
author_facet |
Iwona Hus Joanna Gonet-Sebastianka Agata Surdacka Agnieszka Bojarska-Junak Jacek Roliński |
author_sort |
Iwona Hus |
title |
Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine |
title_short |
Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine |
title_full |
Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine |
title_fullStr |
Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine |
title_full_unstemmed |
Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine |
title_sort |
analysis of peripheral blood immune cells after prophylactic immunization with hpv-16/18 aso4-adjuvanted vaccine |
publisher |
Index Copernicus International S.A. |
series |
Postępy Higieny i Medycyny Doświadczalnej |
issn |
0032-5449 1732-2693 |
publishDate |
2015-04-01 |
description |
Persistent infection with oncogenic types of human papillomavirus (HPV) is a causal factor for more than 99% of cervical cancers. Recently, prophylactic vaccines have been developed to prevent infections with cancer-associated HPV types (HPV16 and HPV18). The aim of this study was to analyze the changes in the immune system that occur within four weeks of the first dose of HPV-16/18 ASO4-adjuvanted vaccine. Assessment of the percentages of selected cell populations in peripheral blood of 20 healthy volunteers vaccinated with Cervarix was performed using flow cytometry. The analysis revealed an increase in the proportion of activated B and CD4+ T helper cells and an absence of significant differences in cytotoxic CD8+ T lymphocytes, indicating activation of the humoral response after vaccination, without a significant effect on cellular response. There were no significant changes in the NK cell population, and there was a reduction of the percentage of NKT-like cells, which may result from expiry of the primary response at the time of analysis. The presented results are preliminary, and in the context of the increasing use of the anti-HPV vaccine, it would be worth continuing the study in larger groups of patients and at earlier and later time points in combination with the measurement of specific anti-HPV16 and -HPV18 antibody levels. Such an assessment could therefore contribute not only to better understanding of the exact mechanism of action of the vaccine, but also to defining the immunological parameters that determine its effectiveness.
|
topic |
cervical cancer human papilloma virus (HPV) prophylactic vaccine immune cell response |
url |
http://phmd.pl/gicid/01.3001.0009.6529 |
work_keys_str_mv |
AT iwonahus analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine AT joannagonetsebastianka analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine AT agatasurdacka analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine AT agnieszkabojarskajunak analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine AT jacekrolinski analysisofperipheralbloodimmunecellsafterprophylacticimmunizationwithhpv1618aso4adjuvantedvaccine |
_version_ |
1725589746351079424 |